ISUP 2 prostate cancer with suspicion of extraprostatic extension on MRI: Prostatectomy results and oncologic outcomes
BACKGROUND: International Society of Uro-Pathology (ISUP) grade group 2 prostate cancer (GG2 PCa) with suspicion of extraprostatic extension (EPE) on preoperative multiparametric MRI (mpMRI) presents a paradox: an histologically favorable intermediate-risk tumor with aggressive imaging features. We aimed to characterize this population, and identify predictors of pathological upgrading, downstaging, and oncological outcomes after robot-assisted radical prostatectomy (RARP). MATERIALS AND METHODS: We analyzed data from 150 patients across 8 European centers with MRI-targeted biopsy-confirmed GG2 PCa and mpMRI-suspected EPE (icT3a), stratified by EPE score, who underwent RARP between 2019 and 2024. Primary endpoint was predictors of pathological upgrading (GG ≥ 3); secondary endpoints included downstaging (pT2), surgical margins, and biochemical recurrence (BCR)-free survival. RESULTS: Patients were divided by EPE score: low (1-2, n = 87) and high (3, n = 38). Pathological upgrading occurred in 36% (55/150), including 10% to GG 4-5. High EPE score was the only significant predictor. Conversely, 46% (69/150) were downstaged to pT2, with low EPE score as main predictor. Positive surgical margins were observed in 30% (45/150). At a median follow-up of 28 months (IQR 17-43), 5-year BCR-free survival was 67% (95% CI 53-85). Posterior/apical EPE on MRI and cT3a stage were linked to higher BCR risk. CONCLUSIONS: GG2 PCa with mpMRI-suspected EPE is heterogeneous, showing risks of both upgrading and organ-confined disease. EPE score was the main predictor of both. Despite imaging suspicion, RARP outcomes remained favorable.
Authors
- R Diamand
- Kateřina Ryšánková
- Claire Siebert
- Alexandre Fourcade (ORCID: https://orcid.org/0000-0003-0484-772X)
- Charles Dariane (ORCID: https://orcid.org/0000-0002-9573-2938)
- Alberto Sasia
- Arthur Peyrottes (ORCID: https://orcid.org/0000-0003-1158-0082)
- Marc‐Olivier Timsit
- Norbert De Brek
- Vincent Benard
- Daniel Benamran (ORCID: https://orcid.org/0000-0003-1287-0567)
- Marco Oderda
- Raquel Matos Da Silva Maia
- Guillaume Ploussard
- Arnaud Méjean
Institutions
- Université Libre de Bruxelles (BE)
- Inserm (FR)
- Institut Jules Bordet (BE)
- Institut Necker Enfants Malades (FR)
- University Hospital Ostrava (CZ)
- Fondazione Ricerca Molinette (IT)
- Assistance Publique – Hôpitaux de Paris (FR)
- Hôpital Européen Georges-Pompidou (FR)
- University Hospital of Geneva (CH)
- Hôpital Européen (FR)
- Institut Claudius Regaud (FR)
- Centre Hospitalier Régional Universitaire de Brest (FR)
- Hôpital Saint-Louis (FR)
- Geneva College (US)
Publication Details
- Journal
- Urologic Oncology Seminars and Original Investigations
- Published
- 2026-05-29
- DOI
- https://doi.org/10.1016/j.urolonc.2026.05.009
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00